Home | Sitemap | Search | ContactA- A A+
   
 
    Public Member Support us  
 

IBCSG 55-17 TOUCH 

Phase II open-label, multicenter, randomized trial of neoadjuvant palbociclib in combination with hormonal therapy and HER2 blockade versus paclitaxel in combination with HER2 blockade for elderly patients with hormone receptor positive/HER2 positive early breast cancer.

DESIGN

please click on the picture to see a larger version

Trial Co-Chairs info
Laura Biganzole, MD, Prato, Italy
Etienne Brain, MD, PhD, Paris, France

Lead Trial Coordinator
Holly Shaw

Trial Coordinator
Colleen King

Data Manager
Colleen King

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email:
ibcsg55_TOUCH@fstrf.org

IBCSG Coordinating Center, Bern, Switzerland
Phone: +41 31 511 94 00
Fax: +41 31 511 94 01
Email:
TOUCH-monitoring@ibcsg.org

Date of Activation
xx 

Targeted Accrual
xx


News

23.03.2019:
The next IBCSG Annual Meeting will take place in Vienna Austria on March 23 and 24, 2019.       

20.03.2019:
16th St. Gallen International Breast Cancer Conference Primary Therapy of Early Breast Cancer

09.10.2018:
Clinical Trials

All News

 
  Print